Reaction

Immune-Mediated Enterocolitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,480 reports · 64 co-occurring drugs

As of the last recalculation, Immune-Mediated Enterocolitis appears in 3,480 FAERS reports alongside 64 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 228.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ipilimumab	1,121	228.7	234.8
Nivolumab	1,471	156.9	159.3
Pembrolizumab	1,091	89.9	90.8
Durvalumab	224	70.3	71.1
Pemetrexed	151	44.0	44.3
Pemetrexed Disodium	212	35.4	35.6
Atezolizumab	187	30.4	30.5
Carboplatin	534	29.5	29.6
Lenvatinib	139	26.4	26.5
Paclitaxel (Aibumin-Bound)	284	22.4	22.5
Paclitaxel	320	21.2	21.2
Loperamide Hydrochloride Oral	26	15.3	15.4
Loperamide Hcl	26	12.2	12.2
Granisetron Hydrochloride	20	11.5	11.5
Encorafenib	18	10.9	10.9
Aprepitant	33	10.8	10.8
Granisetron	18	10.3	10.3
Cisplatin	125	9.9	9.9
Febuxostat Tablets 40 Mg	16	9.4	9.5
Febuxostat Tablets 80 Mg	16	9.4	9.5
Cabozantinib	74	9.4	9.4
Rabeprazole	34	9.3	9.3
Oxaliplatin	91	7.5	7.5
Dronabinol	10	7.5	7.5
Magnesium Oxide	50	7.2	7.2
Etoposide	80	6.6	6.6
Bevacizumab	128	6.4	6.4
Ursosiol	20	6.2	6.2
Trametinib	24	6.0	6.0
Loperamide Hydrochloride	44	5.9	6.0
Ganciclovir	10	5.9	5.9
Fexofenadine Hcl	9	5.8	5.8
Febuxostat	16	5.7	5.7
Ganciclovir Sodium	10	5.7	5.7
Desloratadine	10	5.6	5.6
Ursodiol	20	5.5	5.5
Fluorouracil Cream, 0.5%	69	5.5	5.5
Fluorouracil	69	5.4	5.4
Bendamustine Hcl	14	5.4	5.4
Dexamethasone Sodium Phosphate	9	5.3	5.3
Brentuximab Vedotin	9	5.3	5.3
Trimethoprim	10	5.1	5.1
Cholestyramine	10	5.0	5.0
Axitinib	16	4.9	4.9
Prednisolone	143	4.9	4.9
Prednisolone Oral	143	4.9	4.9
Prednisolone Oral Solution	143	4.9	4.9
Gemcitabine Hydrochloride	43	4.9	4.9
Entecavir	9	4.6	4.6
Vedolizumab	62	4.4	4.4
Fosaprepitant Dimeglumine	10	4.4	4.4
Metoclopramide	39	4.3	4.3
Rabeprazole Sodium	19	4.2	4.2
Pitavastatin Calcium	7	4.1	4.1
Melphalan Hydrochloride	17	4.1	4.1
Melphalan	15	4.0	4.0
Gemcitabine	25	3.8	3.8
Vincristine Sulfate	16	3.3	3.3
Canakinumab	5	2.8	2.8
Tofacitinib Citrate	6	2.7	2.7
Dabrafenib	9	2.6	2.6
Fexofenadine Hydrochloride	9	2.5	2.5
Docetaxel Anhydrous	25	2.2	2.2
Docetaxel	25	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.